Danielle Grams- Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
A commentary on
Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria
by Ibrahim, M. X., Sayin, V. I., Akula, M. K., Liu, M., Fong, L. G., Young, S. G., et al. (2013). Science 340:1330. doi: 10.1126/science.1238880
Hutchinson-Gilford progeria (HGPS) is a rare, genetic progeroid disorder that causes premature ageing, nuclear lamina shape abnormalities, growth impairment, and early death at ~13 year of age (Gordon et al., 2013). The disorder is a result of a spontaneous point mutation in the gene lamin A/C (LMNA) which encodes for the nuclear lamina scaffold protein, prelamin A. The most common point mutation occurs within exon 11 and results in a silent Gly-to-Gly mutation that causes increased usage of an internal cryptic splice site. This cryptic splice site produces a truncated form of prelamin A known as progerin (Eriksson et al., 2003). In non-mutated cells, prelamin A undergoes a series of modifications to produce lamin A, a vital nuclear lamina structural protein. Prelamin A contains a carboxyterminal CAAX motif that is farnesylated on the CAAX motif cysteine by farnesyltransferase (FTase). Farnesylation then targets prelamin A to the inner nuclear membrane where the last three amino acids are cleaved by zinc metallopeptidase STE24 (ZMPSTE24). This is followed by immediate methylation of the farnesylcysteine by isoprenylcysteine carboxyl methyltransferase (ICMT) and subsequent cleavage by ZMPSTE24 to produce lamin A. Following cleavage from the nuclear membrane, lamin A is capable of migrating to the nucleoplasm. In HGPS, progerin lacks a vital cleavage site utilized by ZMPSTE24. This results in progerin remaining permanently attached to the inner nuclear membrane and is suspected to contribute the HGPS phenotype (Fantle et al., 1994; Davies et al., 2009).
Although previous studies have been dedicated to treating HGPS by halting farnesylation via FTase inhibitors, Ibrahim et al. targeted Icmt expression as a means to reverse progeria-like symptoms in a mouse model of HGPS (Ibrahim et al., 2013). Methylation of other CAAX protein motifs has been shown to play a role in protein membrane targeting (Bergo et al., 2002; Michaelson et al., 2005). To explore the role of CAAX methylation in HGPS, Ibrahim et al. introduced a hypomorphic allele of Icmt into a mouse model of HGPS that utilizes Zmpste24 deficient mice. It was found that the mice hypomorphic for Icmt had increased body weight, normalized grip strength, decreased bone fractures and decreased death compared to non-hypomorphic mice.
Analysis of primary mouse embryonic fibroblasts obtained from sacrificed mice indicate that reduced ICMT activity does not affect levels of prelamin A, but instead causes mislocalization of prelamin A away from the nuclear rim. Interestingly, there is not a subsequent reduction in the number of misshapen nuclei in Icmt hypomorphic mice fibroblasts. This indicates that misshapen nuclei play a lesser role in the HGPS phenotype than previously thought. Icmt hypomorphic mice fibroblasts also restored cell proliferation to rates similar to wild type fibroblasts. To further elucidate the role of ICMT within cell proliferation, Ibrahim et al. evaluated the impact of ICMT on the on AKT-mTOR cell growth, proliferation and survival pathway. It was found that reduced ICMT activity triggers prelamin A dependent activation of AKT-mTOR, which decreases premature senescence of Zmpste24 deficient fibroblasts. Furthermore, ICMT activates the pathway through AKT and not mTOR. The precise mechanism of interaction was not determined.
The findings of the Ibrahim et al. study are interesting not only to the field of progeroid disorders, but to the field of ageing studies at large. Scaffidi and Misteli found that dermal fibroblasts with wild type LMNA are capable of utilizing the cryptic spice site seen in HGPS cells. The truncated protein was not found to accumulate with age, but the localization of the protein shifted from the nucleoplasm to the nuclear rim with increasing age (Scaffidi and Misteli, 2006). Other studies have found mixed results with some reporting a direct correlation between progerin accumulation and age and others finding no association (McClintock et al., 2007; Cao et al., 2011). Progerin accumulation has also been linked to telomere dysfunction in normal human fibroblasts. Cells utilizing the LMNA cryptic splice site have shorter telomeres and high senescence-associated β-gal activity (Cao et al., 2011).
Thus, the LMNA splice site plays a critical role not only in HGPS but also in normal ageing and cellular senescence. The Ibrahim et al. study has provided promising results for preventing progerin accumulation at the nuclear rim by reducing ICMT activity. Finding endogenous and exogenous mediators that can control the ICMT activity seen in aging conditions is an important step to discover pharmaceutical intervention and even possible reverse aging. Understanding the influence of ICMT in aging is likely to provide important insights that will not only guide investigation of the molecular and cellular basis of aging, but may also help to identify novel treatment strategies targeting these pathways.
Acknowledgments
Narasaiah Kolliputi was funded by the American Heart Association National Scientist Development Grant 09SDG2260957 and National Institutes of Health R01 HL105932 and the Joy McCann Culverhouse Endowment to the Division of Allergy and Immunology.
References
Bergo, M. O., Gavino, B., Ross, J., Schmidt, W. K., Hong, C., Kendall, L. V., et al. (2002). Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U.S.A. 99, 13049–13054. doi: 10.1073/pnas.192460799
Cao, K., Blair, C. D., Faddah, D. A., Kieckhaefer, J. E., Olive, M., Erdos, M. R., et al. (2011). Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J. Clin. Invest. 121, 2833–2844. doi: 10.1172/JCI43578
Davies, B. S., Fong, L. G., Yang, S. H., Coffinier, C., and Young, S. G. (2009). The posttranslational processing of prelamin A and disease. Annu. Rev. Genomics Hum. Genet. 10, 153–174. doi: 10.1146/annurev-genom-082908-150150
Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., et al. (2003). Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293–298. doi: 10.1038/nature01629
Fantle, K., Trujillo, M., McLain, T., Kupfer, A., and Dalton, M. (1994). The processing pathway of prelamin. A. J. Cell Sci. 107, 61–67.
Gordon, L. B., Brown, W. T., and Collins, F. S. (2013). “Hutchinson-Gilford progeria syndrome,” in GeneReviews, eds R. A. Pagon, M. P. Adam, T. D. Bird, C. R. Dolan, C. T. Fong, and K. Stephens (Seattle, WA: University of Washington, Seattle). Available online at: http://www.ncbi.nlm.nih.gov/books/NBK1121/
Ibrahim, M. X., Sayin, V. I., Akula, M. K., Liu, M., Fong, L. G., Young, S. G., et al. (2013). Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 340, 1330–1333. doi: 10.1126/science.1238880
McClintock, D., Ratner, D., Lokuge, M., Owens, D. M., Gordon, L. B., Collins, F. S., et al. (2007). The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2:e1269. doi: 10.1371/journal.pone.0001269
Michaelson, D., Ali, W., Chiu, V. K., Bergo, M., Silletti, J., Wright, L., et al. (2005). Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell 16, 1606–1616. doi: 10.1091/mbc.E04-11-0960
Citation: Grams D, Lockey R and Kolliputi N (2013) Is isoprenylcysteine carboxyl methyltransferase the key to reverse ageing? Front. Aging Neurosci. 5:40. doi: 10.3389/fnagi.2013.00040
Received: 25 July 2013; Accepted: 26 July 2013;
Published online: 14 August 2013.
Edited by:
P. Hemachandra Reddy, Oregon Health and Science University, USACopyright © 2013 Grams, Lockey and Kolliputi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: nkollipu@health.usf.edu